Sentynl acquires CUTX-101, Copper Histidinate, for $20 million in upfront and regulatory milestone payments through NDA approval, as well as potential sales milestones plus royalties
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://d1io3yog0oux5.cloudfront.net/_7938932611f16ff35e43acba90fd8d5d/fortressbiotech/news/2021-02-24_Cyprium_Therapeutics_a_Fortress_Biotech_Partner_331.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (4)
Alternatively, you can try searching for similar contracts:
